Targeting of anti-tumor responses with bispecific antibodies.
about
The evolving role of catumaxomab in gastric cancerAnti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3 x CD19 bispecific antibody to proliferate and become cytotoxic.
P2860
Targeting of anti-tumor responses with bispecific antibodies.
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Targeting of anti-tumor responses with bispecific antibodies.
@ast
Targeting of anti-tumor responses with bispecific antibodies.
@en
type
label
Targeting of anti-tumor responses with bispecific antibodies.
@ast
Targeting of anti-tumor responses with bispecific antibodies.
@en
prefLabel
Targeting of anti-tumor responses with bispecific antibodies.
@ast
Targeting of anti-tumor responses with bispecific antibodies.
@en
P2093
P1433
P1476
Targeting of anti-tumor responses with bispecific antibodies
@en
P2093
Garrido MA
Wunderlich JR
P304
P356
10.1016/S0171-2985(11)80655-8
P577
1992-08-01T00:00:00Z